Bristol-Myers Squibb Co. (BMY) Tops Q1 EPS by 3c; Boosts FY14 Profit Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. VZ
10. LMT

Go back to Bristol-Myers Squibb Co. (BMY) Tops Q1 EPS by 3c; Boosts FY14 Profit Outlook

Bristol-Myers Squibb Co. (BMY) to Acquire iPierian for for Up to $725M

April 29, 2014 7:19 AM EDT

Bristol-Myers Squibb Co. (NYSE: BMY) acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

The acquisition gives Bristol-Myers Squibb full rights to iPierians lead asset IPN007, an innovative preclinical monoclonal antibody that represents a promising new approach to treat progressive supranuclear palsy (PSP) and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early... More